Insight
Amgen: Denmark - a preferred location for clinical trials and research
Amgen, a worldwide pioneer in biotechnology, partnered with Denmark’s main clinical trial organisation, Trial Nation, paving the way for more trials in Denmark in the future.
Amgen invests heavily in innovative medicines, transformative research and world-class bio-manufacturing. Amgen is present in approximately 100 countries reaching millions of people in the fight against serious illnesses.
In 2019, Amgen acquired the Copenhagen-based biopharmaceutical company Nuevolution, now known as Amgen Research Copenhagen. The acquisition of Nuevolution and its DNA-encoded library platform radically expanded Amgen’s small molecule screening capability.
Denmark is one of Amgen’s preferred locations for running clinical trials. This brings important experimental therapies to Danish patients with no other treatment options available, while also contributing valuable knowledge to the research community in Denmark.
"Denmark has a strong position in Amgen when it comes to competing with other countries on where the clinical trials should be placed. This is based on the fact that Denmark has a long tradition for clinical research and a lot of interest and experience in this field. Consequently, sites in Denmark typically deliver trial data of high quality and within agreed timelines. Despite our small size, Amgen Denmark is in the top league and that is definitely something to be proud of."
Denmark has the second highest number of clinical trials per capita in Europe and also ranks the best country in Europe for biotech research and development in 2019 (Nordic Life Science News).
"The fact that Amgen has chosen Denmark as one of its preferred locations for clinical trials will undoubtedly strengthen the clinical research in Denmark for the benefit of patients, the healthcare system and companies. Invest in Denmark is confident that the partnership between Amgen and Trial Nation will contribute to a ensuring that Denmark remains one of the leading European countries in clinical research."
Support from Invest in Denmark
Invest in Denmark has been in dialogue with Amgen since 2013, with a main focus on trying to attract clinical research and other R&D activities to Denmark. Amgen’s core activities highly correlate with the strong competencies available in Denmark within oncology, cardiovascular and neuroscience. The provided services have included introducing Amgen to the Danish life science cluster and opportunities in Denmark, understanding the framework conditions and establishment process and facilitating meetings with relevant partner organizations in relation to setting up clinical trials.Join Denmark’s life sciences cluster and turn clinical research into business
Denmark has one of the strongest life sciences clusters in the world with a respected international health research laboratory. Political focus on the area has created the best possible framework conditions for biotechnology research and development, attracting strong industry players like Amgen. The Danish government recently announced a new life sciences strategy which will further improve the conditions for research and development – including clinical trials, the use of health data and secure a highly skilled workforce.
Denmark has a strong tradition for public-private partnerships and the Trial Nation network of disease-specific research centres is well placed at Danish university hospitals to conduct clinical trials. Trial Nation brings more than 30 leading private companies and public authorities together with the common objective to strengthen clinical research in Denmark.
"We need strong and innovative Public-Private Partnerships to make Denmark an even more attractive place to run clinical research. Therefore, we are very happy to work with our peers in Trial Nation with the common goal of strengthening the clinical trial activities in Denmark. It’s very successful. Denmark has a lot of opportunities to build on and it is fantastic to see how far we get by working together. I see a great future with huge foreign investments in Danish clinical research, because we are continuously developing our research environment and business framework."
Get to know Amgen
Amgen focuses on areas of high unmet medical needs and leverages its expertise to strive for solutions that dramatically improve people's lives and is developing a pipeline of medicines with breakaway potential. As a biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading companies in the industry.Get in touch Want to know more about clinical trials in Denmark?
Please contact our dedicated experts here:
Loading...